At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Durvalumab +3 moredrug
Likely dose
Durvalumab 1500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized Controlled Study to Evaluate the Efficacy and Safety of Durvalumab Combined With Neoadjuvant Therapy in Patients With Local Advanced Esophageal Squamous Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Durvalumab, Carboplatin, and 2 other interventions for Esophageal Squamous Cell Carcinoma. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This is a study to evaluate the efficacy and safety of preoperative treatment with durvalumab combined with neoajuvant therapy (carboplatin, paclitaxel with/without radiation) in locally advanced resectable oesophageal squamous carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Squamous Cell Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartJun 2020
First PostedSep 2020
Primary CompletionDec 2023
Study CompletionJan 2024
TodayJul 2026
First PostedSep 29, 2020
Enrollment StartJun 19, 2020
Primary CompletionDec 1, 2023
Study CompletionJan 1, 2024
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 5.8 years ago
Interventions
Durvalumabdrug
Durvalumab 1500mg i.v. day 1-22-43-64
Carboplatindrug
Chemotherapy
Paclitaxeldrug
Chemotherapy
Radiotherapy 23 x 1.8 Gyradiation
Radiotherapy 23 x 1.8 Gy